Fu, P; Hughes, J; Zeng, G et al. (2016) A comparative investigation of methods for longitudinal data with limits of detection through a case study. Stat Methods Med Res 25:153-66
|
Ahmad, Md Faiz; Huff, Sarah E; Pink, John et al. (2015) Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators. J Med Chem 58:9498-509
|
Wildey, Gary; Chen, Yanwen; Lent, Ian et al. (2014) Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. PLoS One 9:e106784
|
Kunos, Charles A; Sherertz, Tracy M (2014) Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer. Front Oncol 4:184
|
Mittal, Kriti; Koon, Henry; Elson, Paul et al. (2014) Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther 15:975-81
|
Schwandt, Anita; von Gruenigen, Vivian E; Wenham, Robert M et al. (2014) Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs 32:729-38
|
Chee, Cheng Ean; Krishnamurthi, Smitha; Nock, Charles J et al. (2013) Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist 18:1091-2
|
Shibata, Stephen I; Chung, Vincent; Synold, Timothy W et al. (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631-9
|
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
|
Savvides, Panayiotis; Nagaiah, Govardhanan; Lavertu, Pierre et al. (2013) Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23:600-4
|
Showing the most recent 10 out of 59 publications